Sun Pharma reports Q3FY26 results
Read More
Sun Pharma reports Q2FY26 results
Read More
Sun Pharma reports Q1FY26 results
Read More
Sun Pharma’s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint
Read More
Recent Comments